Explore 3 Stock Ideas & Industry Insights Download Free Report

Stocks

Avista Corp. Reports Financial Results for the First Quarter of 2025, Confirms 2025 Earnings Guidance

SPOKANE, Wash., May 07, 2025 (GLOBE NEWSWIRE) -- Avista Corp. (NYSE: AVA) today announced financial results for the first quarter of 2025. Net income and earnings per diluted share for the first quarter of 2025 compared to the first quarter of 2024 are presented …

EODHD | 07 May 2025

Growing Need for Operational and Cyber Resilience Dominates Concerns Among Financial Services Industry

Outdated legacy systems leaving firms vulnerable to mounting cyber risks, according to Broadridge NEW YORK, May 7, 2025 /PRNewswire/ -- Growing concerns over operational and cyber resilience were the major theme of the SIFMA Ops 2025 conference, a gathering of top operations and technology …

EODHD | 07 May 2025

CDW Declares Quarterly Cash Dividend of $0.625 Per Share

Reinforces Ongoing Commitment to Delivering Value to Stockholders VERNON HILLS, Ill., May 07, 2025--(BUSINESS WIRE)--CDW Corporation (Nasdaq: CDW), a leading multi-brand provider of information technology solutions to business, government, education and healthcare customers in the United States, the United Kingdom and Canada, today announced …

EODHD | 07 May 2025

Vertex Announces First Quarter 2025 Financial Results

Vertex Inc. KING OF PRUSSIA, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results for its first quarter ended March 31, 2025. “Vertex continued to perform …

EODHD | 07 May 2025

Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)

PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that naxitamab-gqgk (DANYELZA®) …

EODHD | 07 May 2025

CRH First Quarter 2025 Earnings: EPS Misses Expectations

CRH (NYSE:CRH) First Quarter 2025 Results Key Financial Results Revenue: US$6.76b (up 3.4% from 1Q 2024). Net loss: US$101.0m (down by 190% from US$112.0m profit in 1Q 2024). US$0.15 loss per share (down from US$0.16 profit in 1Q 2024). AI is about to change …

EODHD | 07 May 2025

Hims & Hers Health First Quarter 2025 Earnings: Beats Expectations

Hims & Hers Health (NYSE:HIMS) First Quarter 2025 Results Key Financial Results Revenue: US$586.0m (up 111% from 1Q 2024). Net income: US$49.5m (up 345% from 1Q 2024). Profit margin: 8.4% (up from 4.0% in 1Q 2024). The increase in margin was driven by higher …

EODHD | 07 May 2025

TransAlta Reports First Quarter 2025 Results and Reaffirms Annual Guidance

TransAlta Corporation CALGARY, Alberta, May 07, 2025 (GLOBE NEWSWIRE) -- TransAlta Corporation (TransAlta or the Company) (TSX: TA) (NYSE: TAC) today reported its financial results for the first quarter ended March 31, 2025. "Our business delivered strong operational performance across the fleet during the …

EODHD | 07 May 2025

Acushnet (NYSE:GOLF) Posts Better-Than-Expected Sales In Q1

Golf equipment and apparel company Acushnet (NYSE:GOLF) reported Q1 CY2025 results topping the market’s revenue expectations , but sales were flat year on year at $703.4 million. Its GAAP profit of $1.62 per share was 22.9% above analysts’ consensus estimates. Is now the time …

EODHD | 07 May 2025

Viper Energy First Quarter 2025 Earnings: EPS Beats Expectations

Viper Energy (NASDAQ:VNOM) First Quarter 2025 Results Key Financial Results Revenue: US$245.0m (up 26% from 1Q 2024). Net income: US$75.0m (up 73% from 1Q 2024). Profit margin: 31% (up from 22% in 1Q 2024). The increase in margin was driven by higher revenue. EPS: …

EODHD | 07 May 2025
Support

Hi! How can we help you today?

Loading…